

Pot, Atom and Step Economy Synthesis: A Diversity-Oriented Approach to Construct 2-substituted Pyrrolo[2,1-*f*][1,2,4]triazin-4(3*H*)-ones

Haoyue Xiang, Yanhong Chen, Qian He, Yuyuan Xie and Chunhao Yang*

*State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China. Fax: 86-21-50806770; Tel: 86-21-50806770; E-mail: chyang@mail.shnc.ac.cn.

Supporting Information

List of contents


Experiment procedures.....	s2-s13
Notes and references.....	s14
X-ray crystallography of compound D17, D23, D30.....	s15-s17
¹ H NMR, ¹³ C NMR.....	s18-s60

1. Experimental procedures

General information

Unless otherwise noted, all solvents and other reagents are commercially available and used without further purification. ^1H and ^{13}C NMR spectra were recorded on Varian Mercury-300/400 and Varian Mercury-400/500 spectrometers. MS and HRMS spectra were performed on a Finnigan MAT 95 spectrometer. Melting points were measured by Büchi 510 melting point apparatus without further corrected.

Preparation of the starting material substituted 3-formyl-4-chromenones¹



Dimethylformamide (6.0 mL) was cooled in ice-cold water and 2-hydroxy acetophenone (0.01 mmol) was added to this with vigorous stirring; phosphorus oxychloride (2.0 mL) was slowly added into the solution. The pink colour thick mass was kept overnight at room temperature. The mixture was then decomposed by cold water and extracted by EtOAc (3 × 100 mL). Concentrated under reduced pressure, the crude product was further purified by column chromatography (PE: EtOAc 10:1).



6-Methyl-4-oxo-4H-chromene-3-carbaldehyde (B2)

Yellow solid (64%). Mp 164-166 °C. ^1H NMR (300 MHz, CDCl_3) δ = 10.38 (s, 1H), 8.52 (s, 1H), 8.07 (s, 1H), 7.55 (d, 1H, J = 8.6 Hz), 7.42 (d, 1H, J = 8.6 Hz), 2.48 (s, 3H). IR (KBr) 3082, 2856, 1695, 1655, 1616, 1485, 949, 891, 825, 773, 545 486 cm^{-1} .

6-Chloro-4-oxo-4H-chromene-3-carbaldehyde (B3)


Yellow solid (89%). Mp 94-96 °C. ^1H NMR (300 MHz, CDCl_3) δ = 10.36 (s, 1H), 8.54 (s, 1H), 8.25 (d, 1H, J = 2.6 Hz), 7.70 (dd, 1H, J = 8.9, 2.6 Hz), 7.51 (d, 1H, J = 8.9 Hz). IR (KBr) 3074, 2977, 2881, 1651, 1623, 1604, 1568, 1463, 1443, 1388, 1338, 1307, 1089, 1049, 997, 923, 842, 636, 543 cm^{-1} .

Preparation of the starting material compound A




Methyl 1-amino-5-bromo-1H-pyrrole-2-carboxylate

Preparation according to the literature (WO2007/150001 A1, 2007), K_2CO_3 was used here to instead of NaOH. Yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 6.82 (d, J = 4.5 Hz, 1H), 6.11 (d, J = 4.5 Hz, 1H), 5.65 (s, 2H), 3.82 (s, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 161.40, 120.73, 115.54, 111.26, 108.62, 51.36.




1-Amino-5-bromo-1H-pyrrole-2-carboxamide (A2)

Ammonolysis from methyl 1-amino-5-bromo-1H-pyrrole-2-carboxylate using NH_3 in MeOH at 100 °C. Yellow solid. Mp 152-153 °C. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.06 (br s, 1H), 7.26 (br s, 1H), 6.75 (d, J = 4.5 Hz, 1H), 6.57 (br s, 2H), 6.13 (d, J = 4.5 Hz, 1H). ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ 162.51, 124.90, 111.69, 108.34, 107.59. m/z (EI): 205 [M^+ , Br^{81} , 46%], 447 [M^+ , Br^{79} , 49%], 188 (Br^{81} , 100%), 186 (Br^{79} , 98%), 79 (38%). calcd for $\text{C}_5\text{H}_6\text{BrN}_3\text{O}$, 202.9694; found; 202.9678 [M^+ , Br^{79}].



Ethyl 1-amino-5-methyl-1H-pyrrole-2-carboxylate

Preparation according to the literature.² Yellow oil. ¹H NMR (300 MHz, CDCl₃) δ 6.77 (d, *J* = 4.2 Hz, 1H), 5.80 (dd, *J* = 4.2 Hz, 1H), 5.36 (s, 2H), 4.27 (q, *J* = 7.1 Hz, 2H), 1.34 (t, *J* = 7.1 Hz, 3H).




1-Amino-5-methyl-1H-pyrrole-2-carboxamide (A3)

Ammonolysis according to the literature from ethyl 1-amino-5-methyl-1H-pyrrole-2-carboxylate.³ Yellow solid. Mp 170-171 °C. ¹H NMR (400 MHz, DMSO-*d*6) δ 7.93 (br s, 1H), 6.97 (br s, 1H), 6.58 (d, *J* = 4.4 Hz, 1H), 6.38 (br s, 2H), 5.72 (d, *J* = 4.4 Hz, 1H), 2.15 (s, 3H). ¹³C NMR (101 MHz, DMSO-*d*6) δ 163.61, 133.14, 122.45, 110.43, 103.77, 11.66. *m/z* (EI):139 [M⁺, 92%], 122 (100%), 94 (28%).calcd for C₆H₉N₃O, 139.0746;found, 139.0746 [M⁺].

Typical procedure for synthesis of compound D1-40


A mixture of **A** (0.4mmol), **B** (0.4mmol), and CuCl₂·H₂O (0.4mmol) in DMSO (5mL) was kept in the pre-heated 120 °C oil bath for 2h under air atmosphere. After the starting materials converted to the intermediate **C** completely, NaOAc (4 equiv.) and amidines or hydrazines (0.4mmol) were added, and then kept the reaction for another 1h. After the reaction was complete, the reaction was cooled to room temperature, and then diluted by water (40 mL). The mixtures was extracted with EtOAc (3 x 30mL), washed with water and brine, dried over anhydrous Na₂SO₄ and filtered. The solvent was removed under vacuum. The residue was applied on a silica-gel column (using CH₂Cl₂/MeOH=80/1) to afford yellow solid.

Characterization of the compounds




2-(4-Oxo-4H-chromen-3-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (C1)

White solid. Mp 282-284 °C. ¹H NMR (300 MHz, DMSO-*d*6) δ 11.79 (s, 1H), 8.93 (s, 1H), 8.16 (d, *J* = 7.9 Hz, 1H), 7.90 (t, *J* = 7.6 Hz, 1H), 7.77 (d, *J* = 8.4 Hz, 1H), 7.65 (s, 0H), 7.59 (t, *J* = 7.7 Hz, 1H), 6.95 (d, *J* = 5.5 Hz, 1H), 6.59 (dd, *J* = 4.3, 2.6 Hz, 1H). ¹³C NMR (126 MHz, DMSO-*d*6) δ 175.07, 158.58, 156.06, 154.39, 142.78, 135.64, 126.99, 125.81, 123.84, 122.00, 119.22, 119.06, 116.79, 111.04, 108.08. *m/z* (EI):279 [M⁺, 100%], 108 (60%), 80 (10%).calcd for C₁₅H₉N₃O₃, 279.0644;found, 279.0641 [M⁺].




2-(4-(2-Hydroxyphenyl)-2-phenylpyrimidin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one(D1)

Yellow solid (71%). Mp 212-214 °C. ¹H NMR (300 MHz, DMSO-*d*6) δ 11.90 (br 1H), 10.06 (br, 1H), 9.09 (s, 1H), 8.50-8.47 (m, 2H), 7.73 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.63 – 7.51 (m, 3H), 7.45 – 7.37 (m, 1H), 7.28 (ddd, *J* = 8.2, 7.3, 1.8 Hz, 1H), 6.99 (td, *J* = 7.5, 1.1 Hz, 1H), 6.93 – 6.84 (m, 1H), 6.75 (dd, *J* = 8.2, 0.9 Hz, 1H), 6.56 – 6.43 (m, 1H). ¹³C NMR (126 MHz, DMSO-*d*6) δ 164.05, 163.09, 158.62, 155.40, 155.30, 146.14, 136.99, 132.29, 132.00, 131.95, 129.37, 128.57, 124.53, 123.76, 121.74, 119.77, 118.99, 115.83, 110.80, 107.68. *m/z* (EI):381 [M⁺, 100%], 364 (62%), 109 (26%).calcd for C₂₂H₁₅N₅O₂, 381.1226;found, 381.1225 [M⁺].




2-(4-(2-Hydroxyphenyl)-2-(p-tolyl)pyrimidin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D2)

Yellow solid (71%). Mp 258-260 °C. ¹H NMR (300 MHz, DMSO-*d*6) δ 11.91 (s, 1H), 10.03 (s, 1H), 9.06 (s, 1H), 8.39 (d, *J* = 8.1 Hz, 2H), 7.73 (dd, *J* = 7.6, 1.5 Hz, 1H), 7.46 – 7.34 (m, 3H), 7.29 (t, *J* = 7.6 Hz, 1H), 7.00 (t, *J* = 7.6 Hz, 1H), 6.90 (dd, *J* = 4.3, 1.6 Hz, 1H), 6.75 (d, *J* = 8.1 Hz, 1H), 6.51 (dd, *J* = 4.2, 2.8 Hz, 1H), 2.41 (s, 3H). ¹³C NMR (101 MHz, DMSO-*d*6) δ 163.60, 162.52, 158.05, 154.91, 154.80, 145.69, 141.45, 133.86, 131.77, 131.45, 129.50, 128.09, 124.07, 122.97, 121.25, 119.26, 118.51, 115.34, 110.29, 107.17, 21.09. *m/z* (EI): 395 [M⁺, 100%], 378 (71%), 109 (26%). calcd for C₂₃H₁₇N₅O₂, 395.1382; found, 395.1381 [M⁺].




2-(2-(4-Chlorophenyl)-4-(2-hydroxyphenyl)pyrimidin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D3)

Yellow solid (69%). Mp 268-270 °C. ¹H NMR (300 MHz, DMSO-*d*6) δ 11.93 (s, 1H), 10.00 (s, 1H), 9.09 (s, 1H), 8.49 (d, *J* = 7.9 Hz, 2H), 7.73 (d, *J* = 7.7 Hz, 1H), 7.63 (d, *J* = 7.9 Hz, 2H), 7.43 – 7.37 (m, 1H), 7.28 (t, *J* = 7.8 Hz, 1H), 6.98 (t, *J* = 7.5 Hz, 1H), 6.89 (dd, *J* = 4.3, 1.6 Hz, 1H), 6.74 (d, *J* = 8.2 Hz, 1H), 6.49 (dd, *J* = 4.3, 2.7 Hz, 1H). ¹³C NMR (126 MHz, DMSO-*d*6) δ 163.19, 163.07, 158.70, 155.37, 155.28, 146.04, 136.87, 135.85, 132.31, 132.06, 130.33, 129.49, 124.45, 123.96, 121.75, 119.77, 119.00, 115.81, 110.81, 107.68. *m/z* (EI): 417 [M⁺, Cl³⁷ 32%], 415 [M⁺, Cl³⁵ 100%], 398 (62%), 400 (18%), 109 (46%). calcd for C₂₂H₁₄ClN₅O₂, 415.0836; found, 415.0839 [M⁺].



2-(2-(4-Bromophenyl)-4-(2-hydroxyphenyl)pyrimidin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D4)


Yellow solid (69%). Mp 279-281 °C. ¹H NMR (300 MHz, DMSO-*d*6) δ 11.95 (s, 1H), 10.02 (s, 1H), 9.11 (s, 1H), 8.43 (d, *J* = 8.5 Hz, 2H), 7.79 (d, *J* = 8.5 Hz, 2H), 7.74 (d, *J* = 6.8 Hz, 1H), 7.43-7.40 (m, 1H), 7.30 (t, *J* = 7.3 Hz, 1H), 7.00 (t, *J* = 7.6 Hz, 1H), 6.91 (d, *J* = 3.0 Hz, 1H), 6.75 (d, *J* = 8.2 Hz, 1H), 6.57 – 6.42 (m, 1H). ¹³C NMR (126 MHz, DMSO-*d*6) δ 163.20, 158.70, 155.36, 155.28, 146.04, 136.20, 132.43, 132.31, 132.06, 130.54, 125.89, 124.44, 124.00, 121.75, 119.77, 119.00, 115.81, 110.81, 107.69. *m/z* (EI): 461 [M⁺, Br⁸¹ 96%], 459 [M⁺, Br⁷⁹ 100%], 444 (51%), 442 (53%), 109 (61%). calcd for C₂₂H₁₄BrN₅O₂, 459.0331; found, 459.0331 [M⁺].



2-(2-(4-Aminophenyl)-4-(2-hydroxyphenyl)pyrimidin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D5)


Yellow solid (76%). Mp 265-266 °C. ¹H NMR (400 MHz, DMSO-*d*6) δ 11.83 (br s, 1H), 10.11 (br s, 1H), 8.90 (s, 1H), 8.19 (d, *J* = 8.3 Hz, 2H), 7.66 (d, *J* = 7.7 Hz, 1H), 7.42 (s, 1H), 7.26 (d, *J* = 7.6 Hz, 1H), 6.98 (d, *J* = 7.5 Hz, 1H), 6.92 – 6.72 (m, 2H), 6.67 (d, *J* = 7.6 Hz, 2H), 6.51 (s, 1H), 5.86 (br s, 2H). ¹³C NMR (126 MHz, DMSO-*d*6) δ

164.55, 162.58, 158.20, 155.53, 155.28, 152.76, 146.45, 132.02, 131.69, 130.27, 124.60, 123.82, 121.63, 121.47, 119.60, 118.93, 115.87, 113.82, 110.67, 107.53. m/z (EI): 396 [M^+ , 100%], 379 (82%), 109 (36%). calcd for $C_{22}H_{16}N_6O_2$, 396.1335; found, 396.1334 [M^+].




2-(4-(2-Hydroxyphenyl)-2-(o-tolyl)pyrimidin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D6)

Yellow solid (76%). Mp 270-272 °C. 1H NMR (300 MHz, DMSO-*d*₆) δ 11.96 (br s, 1H), 10.07 (br s, 1H), 9.12 (s, 1H), 7.96 (dd, $J = 8.0, 1.7$ Hz, 1H), 7.69 (dd, $J = 7.8, 1.8$ Hz, 1H), 7.48 – 7.32 (m, 4H), 7.27 (ddd, $J = 8.3, 7.3, 1.8$ Hz, 1H), 6.97 (td, $J = 7.5, 1.0$ Hz, 1H), 6.91 (dd, $J = 4.3, 1.6$ Hz, 1H), 6.76 (dd, $J = 8.2, 1.0$ Hz, 1H), 6.52 (dd, $J = 4.3, 2.7$ Hz, 1H), 2.61 (s, 3H). ^{13}C NMR (126 MHz, DMSO-*d*₆) δ 167.05 (s), 162.58 (s), 158.13 (s), 155.38 (s), 155.28 (s), 146.16 (s), 137.65 (s), 137.57 (s), 132.16 (s), 131.94 (s), 131.85 (s), 131.06 (s), 130.38 (s), 126.47 (s), 124.42 (s), 122.99 (s), 121.71 (s), 119.73 (s), 118.99 (s), 115.86 (s), 110.81 (s), 107.68 (s), 21.74 (s). m/z (EI): 395 [100%], 302 (12%), 286 (14%). calcd for $C_{23}H_{17}N_5O_2$, 395.1382; found, 395.1387 [M^+].




2-(4-(2-Hydroxyphenyl)-2-(3-methoxyphenyl)pyrimidin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D7)

Yellow solid (81%). Mp 210-212 °C. 1H NMR (300 MHz, DMSO-*d*₆) δ 11.94 (s, 1H), 10.03 (s, 1H), 9.08 (s, 1H), 8.08 (d, $J = 7.6$ Hz, 1H), 8.00 (s, 1H), 7.73 (d, $J = 7.4$ Hz, 1H), 7.49 (t, $J = 7.9$ Hz, 1H), 7.40 (s, 1H), 7.28 (t, $J = 7.7$ Hz, 1H), 7.16 (d, $J = 7.6$ Hz, 1H), 6.99 (t, $J = 7.5$ Hz, 1H), 6.89 (d, $J = 4.1$ Hz, 1H), 6.74 (d, $J = 8.3$ Hz, 1H), 6.50 (t, $J = 3.4$ Hz, 1H), 3.85 (s, 3H). ^{13}C NMR (126 MHz, DMSO-*d*₆) δ 163.78, 163.03, 160.13, 158.57, 155.40, 155.27, 146.10, 138.44, 132.26, 131.99, 130.51, 124.49, 123.84, 121.74, 120.99, 119.79, 118.99, 117.75, 115.82, 113.41, 110.79, 107.66, 55.72. m/z (EI): 411 [M^+ , 100%], 394 (62%), 109 (28%). calcd for $C_{23}H_{17}N_5O_3$, 411.1331; found, 411.1337.




2-(4-(2-Hydroxyphenyl)pyrimidin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D8)

Yellow solid (71%). Mp 276-278 °C. 1H NMR (300 MHz, DMSO-*d*₆) δ 11.93 (br s, 1H), 10.05 (br s, 1H), 9.34 (s, 1H), 9.00 (s, 1H), 7.58 (d, $J = 7.5$ Hz, 1H), 7.39 (s, 1H), 7.25 (t, $J = 7.4$ Hz, 1H), 6.92 (t, $J = 7.5$ Hz, 1H), 6.89 (d, $J = 3.3$ Hz, 1H), 6.72 (d, $J = 8.2$ Hz, 1H), 6.49 (t, $J = 3.0$ Hz, 1H). ^{13}C NMR (126 MHz, DMSO-*d*₆) δ 162.61, 159.37, 157.96, 155.35, 155.23, 145.94, 132.07, 132.01, 125.73, 124.03, 121.75, 119.66, 118.98, 115.86, 110.81, 107.68. m/z (EI): 305 [M^+ , 100%], 287 (84%), 109 (62%), 108 (40%). calcd for $C_{16}H_{11}N_5O_2$, 305.0913; found, 305.0914 [M^+].




2-(4-(2-Hydroxyphenyl)-2-methylpyrimidin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D9)

Yellow solid (67%). Mp 236-238 °C. ¹H NMR (300 MHz, DMSO-*d*6) δ 11.84 (s, 1H), 10.04 (s, 1H), 8.87 (s, 1H), 7.54 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.43 – 7.33 (m, 1H), 7.23 (td, *J* = 7.3, 1.8 Hz, 1H), 6.98 – 6.80 (m, 2H), 6.71 (d, *J* = 8.2 Hz, 1H), 6.49-6.47 (m, 1H), 2.72 (s, 3H). ¹³C NMR (126 MHz, DMSO-*d*6) δ 168.53, 162.64, 158.06, 155.41, 155.26, 146.18, 132.02, 131.83, 124.07, 122.87, 121.70, 119.55, 118.93, 115.87, 110.74, 107.61, 26.23. *m/z* (EI):417 [M⁺, Cl³⁷ 32%], 319 (100%), 302 (62%), 109 (42%). calcd for C₁₇H₁₃N₅O₂, 319.1069; found, 319.1071 [M⁺].




2-(4-(2-Hydroxyphenyl)-2-isopropylpyrimidin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D10)

Yellow solid (78%). Mp 190-192 °C. ¹H NMR (300 MHz, DMSO-*d*6) δ 11.85 (s, 1H), 10.12 (s, 1H), 8.92 (s, 1H), 7.57 (d, *J* = 7.6 Hz, 1H), 7.50 – 7.31 (m, 1H), 7.24 (t, *J* = 7.8 Hz, 1H), 6.92 (t, *J* = 7.5 Hz, 1H), 6.89 – 6.84 (m, 1H), 6.72 (d, *J* = 8.2 Hz, 1H), 6.52 – 6.44 (m, 1H), 3.26 - 3.19 (m, *J* = 14.2, 7.2 Hz, 1H), 1.34 (d, *J* = 6.9 Hz, 6H). ¹³C NMR (126 MHz, DMSO-*d*6) δ 175.37, 162.53, 158.20, 155.52, 155.23, 146.22, 132.05, 131.87, 124.17, 123.01, 121.69, 119.64, 118.97, 115.91, 110.74, 107.62, 37.44, 22.03. *m/z* (EI):347 [M⁺, 100%], 330 (65%), 109 (34%). calcd for C₁₉H₁₇N₅O₂, 347.1382; found, 347.1380 [M⁺].




2-(2-(tert-Butyl)-4-(2-hydroxyphenyl)pyrimidin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D11)

Yellow solid (75%). Mp 136-138 °C. ¹H NMR (300 MHz, DMSO-*d*6) δ 11.84 (br s, 1H), 10.22 (br s, 1H), 8.95 (s, 1H), 7.59 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.39 (dd, *J* = 2.4, 1.9 Hz, 1H), 7.31 – 7.20 (m, 1H), 6.94 (t, *J* = 7.5 Hz, 1H), 6.89 (dd, *J* = 4.3, 1.6 Hz, 1H), 6.74 (d, *J* = 8.2 Hz, 1H), 6.50 (dd, *J* = 4.3, 2.7 Hz, 1H), 1.43 (s, 9H). ¹³C NMR (126 MHz, DMSO-*d*6) δ 177.16, 162.06, 158.00, 155.64, 155.25, 146.30, 132.03, 131.90, 124.22, 122.56, 121.68, 119.70, 118.98, 115.98, 110.73, 107.62, 29.85. *m/z* (EI):361 [M⁺, 100%], 344 (54%), 109 (18%). calcd for C₂₀H₁₉N₅O₂, 361.1539; found, 361.1532 [M⁺].




2-(4-(2-Hydroxyphenyl)-2-methoxypyrimidin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D12)

Yellow solid (75%). Mp 216-218 °C. ¹H NMR (300 MHz, DMSO-*d*6) δ 11.80 (s, 1H), 9.97 (s, 1H), 8.79 (s, 1H), 7.61 – 7.50 (m, 1H), 7.35 dd, *J* = 7.5, 1.5 Hz 1H), 7.23 (td, *J* = 7.7, 1.8 Hz, 1H), 6.92 (t, *J* = 7.5 Hz, 1H), 6.86 (dd, *J* = 4.2, 1.5 Hz, 1H), 6.71 (d, *J* = 8.1 Hz, 1H), 6.47 (dd, *J* = 4.2, 2.7 Hz, 1H), 4.01 (s, 3H). ¹³C NMR (126 MHz, DMSO-*d*6) δ 165.55, 165.52, 160.81, 155.33, 146.04, 132.02, 131.98, 124.14, 121.60, 120.10, 119.58, 118.89, 115.84, 110.66, 107.52, 55.49. *m/z* (EI):335 [M⁺, 100%], 318 (57%), 109 (60%). calcd for C₁₇H₁₃N₅O₃, 335.1018; found, 335.1018 [M⁺].




2-(2-Cyclopropyl-4-(2-hydroxyphenyl)pyrimidin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D13)

Yellow solid (78%). Mp 212-214 °C. ¹H NMR (300 MHz, DMSO-*d*₆) δ 11.78 (s, 1H), 10.01 (s, 1H), 8.80 (s, 1H), 7.53 (dd, *J* = 7.5, 1.2, 1H), 7.38-7.36 (m, 1H), 7.22 (td, *J* = 7.5, 1.5 Hz, 1H), 6.91 (t, *J* = 7.5 Hz, 1H), 6.86 (dd, *J* = 3.9, 1.3 Hz, 1H), 6.70 (d, *J* = 8.2 Hz, 1H), 6.47 (dd, *J* = 4.2, 2.7 Hz, 1H), 2.36-2.6 (m, 1H), 1.17-1.12 (m, 4H). ¹³C NMR (126 MHz, DMSO-*d*₆) δ 172.30, 162.50, 157.93, 155.39, 155.26, 146.23, 131.99, 131.77, 124.26, 122.60, 121.67, 119.58, 118.91, 115.82, 110.72, 107.58, 18.59, 11.51. *m/z* (EI): 417 [M⁺, Cl³⁷ 32%], 345 [M⁺, 100%], 328 (64%), 109 (42%). calcd for C₁₉H₁₅N₅O₂, 345.1226; found, 345.1223 [M⁺].




2-(4-(2-Hydroxyphenyl)-2-(phenoxymethyl)pyrimidin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D14)

Yellow solid (78%). Mp 206-208 °C. ¹H NMR (300 MHz, DMSO-*d*₆) δ 11.92 (br s, 1H), 10.15 (br s, 1H), 9.02 (s, 1H), 7.52 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.38 (dd, *J* = 2.7, 1.6 Hz, 1H), 7.34 – 7.19 (m, 3H), 7.08 – 6.82 (m, 5H), 6.72 (d, *J* = 8.1 Hz, 1H), 6.49 (dd, *J* = 4.3, 2.7 Hz, 1H), 5.39 (s, 2H). ¹³C NMR (126 MHz, DMSO-*d*₆) δ 166.53, 162.99, 158.62, 158.59, 155.54, 155.23, 145.90, 132.17, 132.08, 130.00, 124.18, 123.73, 121.75, 121.39, 119.65, 118.97, 115.96, 115.18, 110.82, 107.71, 70.40. *m/z* (EI): 411 [M⁺, 100%], 394 [46%], 318 (60%), 183 (20%). calcd for C₂₃H₁₇N₅O₃, 411.1331; found, 411.1343 [M⁺].




2-(2-((2-Chlorophenoxy)methyl)-4-(2-hydroxyphenyl)pyrimidin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D15)

Yellow solid (77%). Mp 95-96 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.97 (s, 1H), 10.14 (s, 1H), 9.03 (s, 1H), 7.52 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.47 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.40 (dd, *J* = 2.7, 1.6 Hz, 1H), 7.32 – 7.22 (m, 2H), 7.18 (dd, *J* = 8.3, 1.5 Hz, 1H), 6.98 (td, *J* = 7.6, 1.4 Hz, 1H), 6.95 – 6.87 (m, 2H), 6.73 (dd, *J* = 8.2, 1.1 Hz, 1H), 6.51 (dd, *J* = 4.3, 2.7 Hz, 1H), 5.54 (s, 2H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 165.64, 162.62, 158.33, 155.19, 154.90, 153.71, 145.58, 131.86, 131.78, 130.23, 128.32, 123.91, 123.39, 121.96, 121.50, 121.39, 119.30, 118.65, 115.61, 114.28, 110.46, 107.35, 70.61. *m/z* (EI): 412 [M⁺, Cl³⁷ 32%], 410 [M⁺, Cl³⁵ 100%], 392 (12%), 183 (16%). calcd for C₂₃H₁₆ClN₅O₃, 445.0942; found, 445.0948 [M⁺].




2-(2-Amino-4-(2-hydroxyphenyl)pyrimidin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D16)

Yellow solid (76%). Mp > 300 °C. ¹H NMR (300 MHz, DMSO-*d*₆) δ 11.56 (s, 1H), 10.68 (s, 1H), 8.44 (s, 1H), 7.42 (t, *J* = 2.1 Hz, 1H), 7.34 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.27 (s, 2H), 7.21 (td, *J* = 8.5, 8.0, 1.9 Hz, 1H), 6.84 (dd, *J* = 4.1, 1.8 Hz, 1H), 6.77 (t, *J* = 8.8 Hz, 1H), 6.51 – 6.42 (m, 1H). ¹³C NMR (126 MHz, DMSO-*d*₆) δ 163.89, 163.34, 160.12, 156.53, 155.26, 146.91, 131.69, 130.97, 122.98, 121.56, 119.14, 118.79, 116.61, 113.87, 110.54, 107.40. *m/z* (EI): 320 [M⁺, 100%], 302 (90%), 109 (84%), 108 (19%). calcd for C₁₆H₁₂N₆O₂, 320.1022; found, 320.1022 [M⁺].




Ethyl 2-amino-6-(2-hydroxyphenyl)-5-(4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)nicotinate (D17)

Yellow solid (84%). Mp 280-282 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.60 (s, 1H), 10.66 (s, 1H), 8.32 (s, 1H), 7.72 (s, 2H), 7.44 (dd, *J* = 2.6, 1.7 Hz, 1H), 7.35 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.20 (ddd, *J* = 8.0, 7.3, 1.7 Hz, 1H), 6.85 (dd, *J* = 4.3, 1.7 Hz, 1H), 6.83 – 6.75 (m, 2H), 6.50 (dd, *J* = 4.3, 2.6 Hz, 1H), 4.34 (q, *J* = 7.1 Hz, 2H), 1.33 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (126 MHz, DMSO-*d*₆) δ 166.28, 159.84, 158.97, 156.34, 155.24, 147.75, 142.75, 131.30, 131.12, 123.97, 121.59, 119.07, 118.80, 116.61, 115.69, 110.57, 107.42, 103.11, 61.31, 14.68. *m/z* (EI): 391[100%], 373 (67%), 109 (67%). calcd for C₂₀H₁₇N₅O₄, 391.1281; found, 391.1280 [M⁺].




2-(5-(2-Hydroxyphenyl)-1-phenyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D18)

Yellow solid (77%). Mp > 300 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.55 (s, 1H), 9.83 (s, 1H), 8.29 (s, 1H), 7.48 – 7.04 (m, 8H), 6.96 – 6.67 (m, 3H), 6.47 (dd, *J* = 4.2, 2.6 Hz, 1H). ¹³C NMR (126 MHz, DMSO-*d*₆) δ 155.71, 155.12, 142.32, 140.20, 140.03, 139.92, 132.56, 131.26, 129.27, 128.17, 124.83, 121.46, 119.22, 118.65, 116.40, 115.99, 113.97, 110.64, 107.64. *m/z* (EI): 369 [M⁺, 100%], 351 (22%), 109 (62%). calcd for C₂₁H₁₅N₅O₂, 369.1226; found, 369.1221 [M⁺].




2-(5-(2-Hydroxyphenyl)-1-(p-tolyl)-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D19)

Yellow solid (72%). Mp > 300 °C. ¹H NMR (300 MHz, DMSO-*d*₆) δ 11.49 (br s, 1H), 9.79 (br s, 1H), 8.25 (s, 1H), 7.28 – 7.01 (m, 7H), 6.92 – 6.66 (m, 3H), 6.45 (dd, *J* = 4.3, 2.6 Hz, 1H), 2.26 (s, 3H). ¹³C NMR (126 MHz, DMSO-*d*₆) δ 155.70, 155.12, 142.36, 139.98, 139.82, 137.65, 132.56, 131.19, 129.70, 124.70, 121.44, 119.21, 118.64, 116.50, 115.98, 113.80, 110.62, 107.62, 20.98. *m/z* (EI): 383 [M⁺, 100%], 365 (20%), 109 (60%). calcd for C₂₂H₁₇N₅O₂, 383.1382; found; 383.1385 [M⁺].




2-(5-(2-Hydroxyphenyl)-1-(4-methoxyphenyl)-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D20)

Yellow solid (65%). Mp 268-270 °C. ¹H NMR (300 MHz, DMSO-*d*₆) δ 11.46 (br s, 1H), 9.79 (br s, 1H), 8.23 (br s, 1H), 7.33 – 6.98 (m, 5H), 6.97 – 6.66 (m, 5H), 6.44 (t, *J* = 3.5 Hz, 1H), 3.72 (s, 3H). ¹³C NMR (126 MHz, DMSO-*d*₆) δ 158.92, 155.72, 155.14, 142.41, 138.88, 139.76, 133.09, 132.57, 131.15, 126.38, 121.43, 119.19, 118.63, 116.50, 115.98, 114.33, 113.56, 110.61, 107.61, 55.79. *m/z* (EI): 399 [M⁺, 100%], 381 (18%), 109 (49%). calcd for C₂₂H₁₇N₅O₃, 399.1331; found, 399.1347 [M⁺].




2-(1-(4-Fluorophenyl)-5-(2-hydroxyphenyl)-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D21)

Yellow solid (75%). Mp 292-293 °C. ^1H NMR (300 MHz, DMSO-*d*6) δ 11.52 (s, 1H), 9.84 (s, 1H), 8.26 (s, 1H), 7.34 – 7.24 (m, 2H), 7.25 – 7.09 (m, 5H), 6.84 (dd, J = 4.3, 1.7 Hz, 1H), 6.82 – 6.72 (m, 2H), 6.45 (dd, J = 4.3, 2.6 Hz, 1H). ^{13}C NMR (126 MHz, DMSO-*d*6) δ 161.47 ((d, J = 245.57 Hz), 155.66, 155.14, 142.26, 140.24, 140.10, 136.46 (d, J = 2.9 Hz), 132.59, 131.36, 127.03 (d, J = 8.8 Hz), 121.46, 119.26, 118.64, 116.16 ((d, J = 23.44 Hz), 116.15, 116.06, 113.91 (s), 110.65, 107.64. m/z (EI): 387 [M^+ , 100%], 369 (22%), 109 (66%). calcd for $\text{C}_{21}\text{H}_{14}\text{FN}_5\text{O}_2$, 387.1132;found; 387.1135 [M^+].




2-(1-(4-Chlorophenyl)-5-(2-hydroxyphenyl)-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D22)

Yellow solid (64%). Mp > 300 °C. ^1H NMR (300 MHz, DMSO-*d*6) δ 11.59 (br s, 1H), 9.81 (br s, 1H), 8.29 (s, 1H), 7.42 (d, J = 8.3 Hz, 2H), 7.27 - 7.17 (m, 5H), 6.85 - 6.79 (m, 3H), 6.45 (s, 1H). ^{13}C NMR (126 MHz, DMSO-*d*6) δ 155.60, 155.12, 142.16, 140.57, 140.04, 138.93, 132.59, 132.58, 131.47, 129.33, 126.35, 121.49, 119.34, 118.65, 116.10, 116.04, 114.17, 110.67, 107.66. m/z (EI): 405 [M^+ , Cl^{37} , 37%], 403 [M^+ , Cl^{35} , 100%], 385 (29%), 109 (96%). calcd for $\text{C}_{21}\text{H}_{14}\text{ClN}_5\text{O}_2$, 403.0836;found; 403.0836 [M^+].




2-(1-(4-Bromophenyl)-5-(2-hydroxyphenyl)-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D23)

Yellow solid (68%). Mp > 300 °C. ^1H NMR (300 MHz, DMSO-*d*6) δ 11.59 (br s, 1H), 9.81 (br s, 1H), 8.30 (s, 1H), 7.55 (d, J = 8.6 Hz, 2H), 7.40 – 7.04 (m, 5H), 6.82 (dt, J = 8.2, 4.5 Hz, 3H), 6.45 (dd, J = 4.1, 2.7 Hz, 1H). ^{13}C NMR (126 MHz, DMSO-*d*6) δ 155.58, 155.11, 142.14, 140.61, 140.00, 139.35, 132.59, 132.26, 131.48, 126.61, 121.49, 121.03, 119.35, 118.65, 116.11, 116.03, 114.20, 110.67, 107.67. m/z (EI): 449 [M^+ , Br^{81} , 86%], 447 [M^+ , Br^{79} , 80%], 431 (Br^{81} , 18%), 433 (Br^{79} , 18%), 109 (74%). calcd for $\text{C}_{21}\text{H}_{14}\text{BrN}_5\text{O}_2$, 447.0331;found; 447.0338 [M^+ , Br^{79}].




2-(5-(2-Hydroxyphenyl)-1-(4-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D24)

Yellow solid (73%). Mp > 300 °C. ^1H NMR (300 MHz, DMSO-*d*6) δ 11.65 (br s, 1H), 9.83 (br s, 1H), 8.35 (s, 1H), 7.75 (d, J = 8.1 Hz, 2H), 7.47 (d, J = 8.2 Hz, 2H), 7.33 – 7.14 (m, 3H), 6.91 – 6.73 (m, 3H), 6.51 – 6.41 (m, 1H). ^{13}C NMR (126 MHz, DMSO-*d*6) δ 155.55, 155.11, 143.29, 142.02, 141.12, 140.21, 132.58, 131.66, 128.13 (q, J = 32.4 Hz, CF_3C), 126.60 (q, J = 3.5 Hz, CF_3CCH), 124.33 (q, J = 272.7 Hz, CF_3), 124.90, 121.52, 119.43, 118.66, 116.15, 115.86, 114.62, 110.70, 107.69. m/z (EI): 437 [M^+ , 100%], 419 (30%), 109 (86%). calcd for $\text{C}_{22}\text{H}_{14}\text{F}_3\text{N}_5\text{O}_2$, 437.1100;found; 437.1103 [M^+].




4-(5-(2-Hydroxyphenyl)-4-(4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)-1H-pyrazol-1-yl)benzonitrile (D25)

Yellow solid (51%). Mp > 300 °C. ¹H NMR (300 MHz, DMSO-*d*6) δ 11.64 (br s, 1H), 9.82 (br s, 1H), 8.35 (s, 1H), 7.85 (d, *J* = 8.4 Hz, 2H), 7.43 (d, *J* = 8.3 Hz, 2H), 7.35 – 7.11 (m, 3H), 6.97 – 6.70 (m, 3H), 6.46 (t, *J* = 3.5 Hz, 1H). ¹³C NMR (126 MHz, DMSO-*d*6) δ 155.51, 155.10, 143.59, 141.91, 141.39, 140.26, 133.66, 132.57, 131.76, 124.81, 121.54, 119.48, 118.66, 118.63, 116.21, 115.77, 114.84, 110.73, 110.46, 107.72. *m/z* (EI): 394 [M⁺, 100%], 376 (27%), 109 (70%). calcd for C₂₂H₁₄N₆O₂, 394.1178; found, 394.1177 [M⁺].




2-(1-(5-Bromopyridin-2-yl)-5-(2-hydroxyphenyl)-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D26)

Yellow solid (52%). Mp 276-278 °C. ¹H NMR (300 MHz, DMSO-*d*6) δ 11.64 (br s, 1H), 9.62 (br s, 1H), 8.35 (d, *J* = 2.6 Hz, 1H), 8.26 (s, 1H), 8.19 (dd, *J* = 8.6, 2.3 Hz, 1H), 7.58 (d, *J* = 8.6 Hz, 1H), 7.30 (t, *J* = 2.1 Hz, 1H), 7.26 – 7.08 (m, 2H), 6.85 (dd, *J* = 4.2, 1.8 Hz, 1H), 6.83 – 6.67 (m, 2H), 6.47 (dd, *J* = 4.2, 2.5 Hz, 1H). ¹³C NMR (126 MHz, DMSO-*d*6) δ 155.14, 155.08, 151.57, 148.91, 142.14, 141.88, 141.28, 140.30, 132.12, 130.96, 121.58, 120.58, 119.27, 119.05, 118.70, 116.53, 115.81, 114.69, 110.71, 107.67. *m/z* (EI): 450 [M⁺, Br⁸¹, 98%], 448 [M⁺, Br⁷⁹, 100%], 433 (Br⁸¹, 50%), 431 (Br⁷⁹, 52%), 275 (72%), 109 (74%). calcd for C₂₀H₁₃BrN₆O₂, 448.0283; found; 448.0282 [M⁺, Br⁷⁹].



2-(1-(2-Chlorophenyl)-5-(2-hydroxyphenyl)-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D27)


Yellow solid (66%). Mp > 300 °C. ¹H NMR (300 MHz, DMSO-*d*6) δ 11.58 (br s, 1H), 9.82 (br s, 1H), 8.27 (s, 1H), 7.53 (dd, *J* = 8.1, 1.7 Hz, 1H), 7.49 – 7.31 (m, 3H), 7.22 (dd, *J* = 2.6, 1.5 Hz, 1H), 7.12 (ddd, *J* = 8.6, 7.3, 1.7 Hz, 1H), 7.01 (dd, *J* = 7.6, 1.7 Hz, 1H), 6.84 (dd, *J* = 4.2, 1.6 Hz, 1H), 6.74 (dd, *J* = 8.3, 1.2 Hz, 1H), 6.67 (td, *J* = 7.4, 1.2 Hz, 1H), 6.45 (dd, *J* = 4.2, 2.7 Hz, 1H). ¹³C NMR (126 MHz, DMSO-*d*6) δ 155.61, 155.19, 142.56, 141.59, 140.38, 137.33, 131.88, 131.48, 131.38, 131.15, 130.53, 130.39, 128.14, 121.44, 118.85, 118.70, 115.90, 115.61, 113.23, 110.59, 107.59. *m/z* (EI): 405 [M⁺, Cl³⁷, 92%], 403 [M⁺, Cl³⁵, 33%], 385 (33%), 109 (100%). calcd for C₂₁H₁₄ClN₅O₂, 403.0836; found; 403.0844 [M⁺, Cl³⁵].



2-(5-(2-Hydroxyphenyl)-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D28)


Yellow solid (48%). Mp 282-283 °C. ¹H NMR (300 MHz, DMSO-*d*6) δ 13.31 (br s, 1H), 11.54 (s, 1H), 9.87 (s, 1H), 8.08 (br s, 1H), 7.63 – 7.28 (m, 2H), 7.22 (t, *J* = 7.6 Hz, 1H), 6.87 (t, *J* = 7.1 Hz, 3H), 6.48 (d, *J* = 4.4 Hz, 1H). ¹³C NMR (126 MHz, DMSO-*d*6) δ 155.33, 155.10, 147.71, 143.80, 139.89, 139.44, 131.49, 131.12, 130.70,

121.40, 119.33, 118.79, 116.40, 116.20, 111.62, 110.43, 107.35. m/z (EI): 293 [M^+ , 100%], 275 (32%), 109 (60%), 108 (11%). calcd for $C_{15}H_{11}N_5O_2$, 293.0913;found, 293.0914 [M^+].




2-(5-(2-Hydroxyphenyl)-1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D29)

Yellow solid (49%). Mp 291-292 °C. 1H NMR (300 MHz, DMSO- d_6) δ 11.43 (br s, 1H), 9.92 (br s, 1H), 8.02 (s, 1H), 7.28 (d, J = 7.9 Hz, 2H), 7.16 (s, 1H), 7.04 – 6.85 (m, 2H), 6.81 (s, 1H), 6.42 (s, 1H), 3.65 (s, 3H). ^{13}C NMR (126 MHz, DMSO- d_6) δ 155.60, 155.20, 142.63, 140.13, 138.42, 132.57, 131.26, 121.32, 119.30, 118.61, 116.22, 116.13, 112.06, 110.50, 107.49, 37.59. m/z (EI): 307 [M^+ , 100%], 289 (12%), 109 (53%). calcd for $C_{16}H_{13}N_5O_2$, 307.1069;found; 307.1069 [M^+].




2-(5-(2-Hydroxyphenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D30)

Yellow solid (48%). Mp 292 °C decomposed. 1H NMR (500 MHz, DMSO- d_6) δ 11.36 (s, 1H), 9.88 (s, 1H), 8.11 (s, 1H), 7.30 (td, J = 7.8, 1.8 Hz, 1H), 7.23 (dd, J = 7.8, 1.7 Hz, 1H), 7.10 (t, J = 2.2 Hz, 1H), 6.94 (d, J = 8.2 Hz, 1H), 6.90 (t, J = 7.4 Hz, 1H), 6.80 (dd, J = 4.3, 1.8 Hz, 1H), 6.41 (dd, J = 4.2, 2.6 Hz, 1H), 4.22 (dt, J = 13.1, 6.6 Hz, 1H), 1.37 (d, J = 6.6 Hz, 3H), 1.29 (d, J = 6.6 Hz, 3H). ^{13}C NMR (126 MHz, DMSO- d_6) δ 155.74, 155.14, 142.61, 139.03, 138.65, 132.47, 131.21, 121.27, 119.44, 118.60, 116.39, 116.16, 111.50, 110.48, 107.50, 50.65, 23.23, 22.52. m/z (EI): 335 [M^+ , 100%], 320 (36%), 109 (66%). calcd for $C_{18}H_{17}N_5O_2$, 335.1382;found; 335.1385 [M^+].




2-(1-(tert-Butyl)-5-(2-hydroxyphenyl)-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D31)

Yellow solid (65%). Mp 248-250 °C. 1H NMR (400 MHz, DMSO- d_6) δ 11.51 (s, 1H), 9.76 (s, 1H), 8.38 (s, 1H), 7.45 – 7.37 (m, 2H), 7.18 (td, J = 8.1, 1.8 Hz, 1H), 6.89 – 6.80 (m, 3H), 6.49 (dd, J = 4.3, 2.6 Hz, 1H), 1.60 (s, 9H). ^{13}C NMR (126 MHz, DMSO- d_6) δ 155.26, 155.24, 146.88, 143.64, 130.57, 129.84, 129.71, 121.40, 120.00, 119.27, 118.82, 116.09, 111.53, 110.45, 107.38, 59.42, 29.72. m/z (EI): 349 [M^+ , 100%], 331 (5%), 293 (46%), 275 (63%), 109 (90%). calcd for $C_{19}H_{19}N_5O_2$, 349.1539;found, 349.1542 [M^+].




2-(1-(2-Hydroxyethyl)-5-(2-hydroxyphenyl)-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D32)

Yellow solid (63%). Mp 210-212 °C. 1H NMR (300 MHz, DMSO- d_6) δ 11.39 (br s, 1H), 9.86 (br s, 1H), 8.07 (s, 1H), 7.29 (t, J = 6.9 Hz, 2H), 7.17 – 7.06 (m, 1H), 6.98 – 6.84 (m, 2H), 6.81 (dd, J = 3.7, 1.9 Hz, 1H), 6.42 (dd, J = 4.3, 2.3 Hz, 1H), 4.82 (br s, 1H), 3.96 (t, J = 6.4 Hz, 2H), 3.66 (br s, 2H). ^{13}C NMR (126 MHz, DMSO- d_6) δ 155.58, 155.18, 142.62, 140.37, 138.75, 132.81, 131.18, 121.30, 119.32, 118.60, 116.21, 116.14, 111.97, 110.49, 107.49, 60.05, 51.87. m/z (EI): 337 [M^+ , 100%], 319 (14%), 294 (22%), 109 (64%). calcd for $C_{17}H_{15}N_5O_3$, 337.1175;found; 337.1181 [M^+].




2-(1-Benzyl-5-(2-hydroxyphenyl)-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D33)

Yellow solid (70%). Mp 258-259 °C. ¹H NMR (300 MHz, DMSO-*d*6) δ 9.96 (br s, 1H), 8.10 (s, 1H), 7.37 – 7.09 (m, 6H), 7.04 – 6.91 (m, 3H), 6.90 – 6.77 (m, 2H), 6.42 (dd, *J* = 4.2, 2.5 Hz, 1H), 5.18 (s, 2H). ¹³C NMR (126 MHz, DMSO-*d*6) δ 155.56, 155.16, 142.55, 140.42, 139.19, 137.37, 132.48, 131.37, 128.79, 127.89, 127.70, 121.34, 119.37, 118.61, 116.25, 116.06, 112.42, 110.53, 107.53, 53.26. *m/z* (EI): 383 [M⁺, 100%], 279 (17%), 109 (78%), 91 (78%). calcd for C₂₂H₁₇N₅O₂, 307.1069;found; 383.1382 [M⁺].




2-(4-(5-Chloro-2-hydroxyphenyl)-2-cyclopropylpyrimidin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D34)

Yellow solid (58%). Mp 266-267 °C. yellow solid ¹H NMR (300 MHz, DMSO-*d*6) δ 11.85 (s, 1H), 10.25 (s, 1H), 8.85 (s, 1H), 7.55 (d, *J* = 2.7 Hz, 1H), 7.44 (dd, *J* = 2.6, 1.7 Hz, 1H), 7.29 (dd, *J* = 8.7, 2.8 Hz, 1H), 6.89 (dd, *J* = 4.3, 1.6 Hz, 1H), 6.72 (d, *J* = 8.7 Hz, 1H), 6.50 (dd, *J* = 4.3, 2.7 Hz, 1H), 2.43 – 2.27 (m, 1H), 1.24 – 1.03 (m, 4H). ¹³C NMR (126 MHz, DMSO-*d*6) δ 172.61, 160.99, 158.07, 155.26, 154.22, 145.99, 131.38, 131.28, 126.22, 122.97, 122.72, 121.77, 118.89, 117.48, 110.78, 107.67, 18.64, 11.67. *m/z* (EI):381 [M⁺, Cl³⁷ 36%], 379 [M⁺, Cl³⁵ 100%], 362 (68%), 344 (38%), 109 (70%). calcd for C₁₉H₁₄ClN₅O₂, 379.0836;found,379.0835 [M⁺].



2-(2-Cyclopropyl-4-(2-hydroxy-5-methylphenyl)pyrimidin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D35)


Yellow solid (69%). Mp 235-236 °C. yellow solid ¹H NMR (300 MHz, DMSO-*d*6) δ 11.78 (s, 1H), 9.75 (s, 1H), 8.80 (s, 1H), 7.41 (br, 1H), 7.37 (br, 1H), 7.05 (d, *J* = 8.2 Hz, 1H), 6.88 (d, *J* = 3.9 Hz, 1H), 6.61 (d, *J* = 8.3 Hz, 1H), 6.49 (s, 1H), 2.34-2.30 (s, 1H), 2.26 (s, 3H), 1.14 (d, *J* = 7.8 Hz, 4H). ¹³C NMR (126 MHz, DMSO-*d*6) δ 172.26, 162.46, 157.91, 155.27, 153.22, 146.35, 132.36, 132.19, 127.84, 123.93, 122.65, 121.69, 118.94, 115.70, 110.67, 107.53, 20.60, 18.62, 11.47. *m/z* (EI):359 [M⁺, 100%], 342 (66%), 109 (46%). calcd for C₂₀H₁₇N₅O₂, 359.1382;found, 359.1382[M⁺]



7-Bromo-2-(2-cyclopropyl-4-(2-hydroxyphenyl)pyrimidin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D36)


Yellow solid (82%). Mp 278-279 °C. ¹H NMR (300 MHz, DMSO-*d*6) δ 12.08 (br s, 1H), 9.93 (br s, 1H), 8.83 (s, 1H), 7.55 (dd, *J* = 7.7, 1.8 Hz, 1H), 7.24 (td, *J* = 7.9, 1.8 Hz, 1H), 6.98 (d, *J* = 4.5 Hz, 1H), 6.93 (td, *J* = 7.5, 1.0 Hz, 1H), 6.73 – 6.63 (m, 2H), 2.33 (tt, *J* = 7.1, 5.4 Hz, 1H), 1.22 – 1.04 (m, 4H). ¹³C NMR (101 MHz, DMSO-*d*6) δ 174.00, 164.26, 159.21, 156.56, 156.13, 148.27, 125.87, 123.81, 121.65, 121.01, 117.10, 114.62, 109.84, 104.65, 20.07, 12.98. *m/z* (EI): 425[M⁺, Br⁸¹, 98%], 423 [M⁺, Br⁷⁹, 100%], 408 (Br⁸¹, 72%), 406 (Br⁷⁹, 68%), 252 (68%),

189 (56%). calcd for $C_{19}H_{14}BrN_5O_2$, 423.0330; found; 423.0331 [M^+ , Br^{79}].




2-(2-Cyclopropyl-4-(2-hydroxyphenyl)pyrimidin-5-yl)-7-methylpyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (D37)

Yellow solid (84%). Mp 244-245 °C. 1H NMR (300 MHz, DMSO-*d*6) δ 11.85 (s, 1H), 9.87 (s, 1H), 8.84 (s, 1H), 7.49 (dd, $J = 7.6, 1.8$ Hz, 1H), 7.23 (t, $J = 7.7$ Hz, 1H), 6.93 (t, $J = 7.5$ Hz, 1H), 6.80 (d, $J = 4.2$ Hz, 1H), 6.67 (d, $J = 8.3$ Hz, 1H), 6.28 (d, $J = 4.7$ Hz, 1H), 2.40 – 2.24 (m, 1H), 1.93 (s, 3H), 1.21 – 1.06 (m, 4H). ^{13}C NMR (126 MHz, DMSO-*d*6) δ 172.32, 163.10, 157.46, 155.29, 154.96, 144.97, 131.52, 131.16, 129.61, 125.18, 122.66, 119.41, 118.02, 115.45, 109.72, 106.91, 18.58, 11.45, 10.56. m/z (EI): 359 [M^+ , 100%], 342 (72%), 123 (38%). calcd for $C_{20}H_{17}N_5O_2$, 359.1382; found, 359.1380 [M^+].




2-(2-Cyclopropyl-4-(2-hydroxyphenyl)pyrimidin-5-yl)quinazolin-4(3H)-one (D38)

Yellow solid (82%). Mp 216-218 °C. 1H NMR (300 MHz, DMSO-*d*6) δ 12.32 (br s, 1H), 9.87 (br s, 1H), 8.82 (s, 1H), 8.09 (d, $J = 7.9$ Hz, 1H), 7.87 – 7.64 (m, 1H), 7.54 (dd, $J = 7.7, 1.8$ Hz, 1H), 7.46 (dd, $J = 8.3, 6.8$ Hz, 1H), 7.40 (d, $J = 8.2$ Hz, 1H), 7.20 (t, $J = 7.7$ Hz, 1H), 6.90 (t, $J = 7.4$ Hz, 1H), 6.63 (d, $J = 8.2$ Hz, 1H), 2.38 – 2.24 (m, 1H), 1.18 – 1.06 (m, 4H). ^{13}C NMR (126 MHz, DMSO-*d*6) δ 171.98, 162.44, 162.26, 157.72, 155.51, 152.56, 149.35, 134.76, 132.00, 131.67, 127.73, 126.95, 126.19, 125.22, 124.42, 121.45, 119.46, 115.71, 18.59, 11.44. m/z (EI): 356 [M^+ , 60%], 339 (100%), 120 (30%). calcd for $C_{21}H_{16}N_4O_2$, 356.1273; found, 356.1281 [M^+].



6-Chloro-2-(2-cyclopropyl-4-(2-hydroxyphenyl)pyrimidin-5-yl)quinazolin-4(3H)-one (D39)

Yellow solid (65%). Mp 228-230 °C. yellow solid 1H NMR (300 MHz, DMSO-*d*6) δ 12.56 (s, 1H), 9.83 (s, 1H), 8.82 (s, 1H), 8.03 (s, 1H), 7.74 (d, $J = 7.4$ Hz, 1H), 7.55 (d, $J = 7.5$ Hz, 1H), 7.41 (d, $J = 8.6$ Hz, 1H), 7.19 (t, $J = 7.4$ Hz, 1H), 6.91 (t, $J = 7.2$ Hz, 1H), 6.62 (d, $J = 8.4$ Hz, 1H), 2.31 (s, 1H), 1.11 (s, 4H). ^{13}C NMR (126 MHz, DMSO-*d*6) δ 172.19, 162.47, 161.38, 157.71, 155.45, 153.22, 148.10, 134.93, 132.07, 131.75, 131.22, 129.98, 125.22, 125.00, 124.43, 122.70, 119.56, 115.70, 18.63, 11.49. m/z (EI): 392 [M^+ , Cl^{37} 25%], 390 [M^+ , Cl^{35} 67%], 373 (100%), 154 (30%). calcd for $C_{21}H_{15}ClN_4O_2$, 390.0884; found, 390.0883 [M^+].



2-(2-Cyclopropyl-4-(2-hydroxyphenyl)pyrimidin-5-yl)-6-methylquinazolin-4(3H)-one (D40)


Yellow solid (72%). Mp 272-273 °C. ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.25 (s, 1H), 9.89 (s, 1H), 8.83 (s, 1H), 7.90 (s, 1H), 7.68 – 7.40 (m, 2H), 7.32 (d, *J* = 8.3 Hz, 1H), 7.24 - 7.18 (m, 1H), 6.91 (t, *J* = 7.1 Hz, 1H), 6.65 (d, *J* = 7.7 Hz, 1H), 2.43 (s, 3H), 2.37 - 2.29 (m, 1H), 1.30 – 0.94 (m, 4H). ¹³C NMR (126 MHz, DMSO-*d*₆) δ 171.88, 162.48, 162.20, 157.73, 155.59, 151.67, 147.40, 136.71, 136.0, 131.96, 131.65, 127.64, 125.58, 125.28, 124.43, 121.23, 119.45, 115.75, 21.28, 18.58, 11.42. *m/z* (EI): 370 [M⁺, 52%], 353 (100%), 134 (26%). calcd for C₂₂H₁₈N₄O₂, 370.1430;found, 370.1430 [M⁺].

2. Notes and References

1. R.G. Nandgaonkar and V.N. Ingle, *Asian J. Chem.*, 2005, **17**, 2016-2018.
2. J. Hynes, W. W. Doubleday, A. J. Dyckman, J. D. Godfrey, J. A. Grosso, S. Kiau and K. Leftheris, *J Org Chem*, 2004, **69**, 1368-1371.
3. M. W. Bundesmann, S. B. Coffey and S. W. Wright, *Tetrahedron Lett*, 2010, **51**, 3879-3882.

3. X-ray crystallography of compound D17, D23 and D30

Datablock: H_Report_20120067_20120067.CIF - ellipsoid plot





D17

A specimen of $C_{20}H_{17}N_5O_4$ was used for the X-ray crystallographic analysis. The X-ray intensity data were measured.

The total exposure time was 5.58 hours. The frames were integrated with the Bruker SAINT software package using a narrow-frame algorithm. The integration of the data using a triclinic unit cell yielded a total of 11939 reflections to a maximum θ angle of 27.57° (0.77 \AA resolution), of which 4057 were independent (average redundancy 2.943, completeness = 96.8%, $R_{\text{int}} = 1.43\%$, $R_{\text{sig}} = 1.23\%$) and 3810 (93.91%) were greater than $2\sigma(F^2)$. The final cell constants of $a = 7.1731(2) \text{ \AA}$, $b = 9.0580(3) \text{ \AA}$, $c = 15.2735(5) \text{ \AA}$, $\alpha = 96.9650(10)^\circ$, $\beta = 93.3370(10)^\circ$, $\gamma = 112.6080(10)^\circ$, volume = $903.39(5) \text{ \AA}^3$, are based upon the refinement of the XYZ-centroids of 9559 reflections above $20 \sigma(I)$ with $4.931^\circ < 2\theta < 55.07^\circ$. Data were corrected for absorption effects using the multi-scan method (SADABS). The ratio of minimum to maximum apparent transmission was 0.926.

The structure was solved and refined using the Bruker SHELXTL Software Package, using the space group P -1, with $Z = 2$ for the formula unit, $C_{20}H_{17}N_5O_4$. The final anisotropic full-matrix least-squares refinement on F^2 with 273 variables converged at $R1 = 3.43\%$, for the observed data and $wR2 = 9.31\%$ for all data. The goodness-of-fit was 1.055. The largest peak in the final difference electron density synthesis was $0.362 \text{ e}^-/\text{\AA}^3$ and the largest hole was $-0.232 \text{ e}^-/\text{\AA}^3$ with an RMS deviation of $0.045 \text{ e}^-/\text{\AA}^3$. On the basis of the final model, the calculated density was 1.439 g/cm^3 and $F(000)$, 408 e^- .

The crystal structure for **D17** has been deposited at the Cambridge Crystallographic Data Center and allocated the reference no. CCDC 909193.




ured.

ing a narrow-
imum θ angle
9.3%, Rint =
= 10.4533(7)
used upon the
corrected for
mission was

with Z = 2 for
les converged
ak in the final
on of 0.056 e-

: reference no.



D30



A specimen of $C_{18}H_{17}N_5O_2$ was used for the X-ray crystallographic analysis. The X-ray intensity data were measured.

The total exposure time was 1.90 hours. The frames were integrated with the Bruker SAINT software package using a narrow-frame algorithm. The integration of the data using a monoclinic unit cell yielded a total of 9884 reflections to a maximum θ angle of 25.00° (0.84 \AA resolution), of which 2794 were independent (average redundancy 3.538, completeness = 97.4%, $R_{\text{int}} = 5.08\%$, $R_{\text{sig}} = 4.98\%$) and 2495 (89.30%) were greater than $2\sigma(F^2)$. The final cell constants of $a = 16.640(8) \text{ \AA}$, $b = 7.053(4) \text{ \AA}$, $c = 14.173(7) \text{ \AA}$, $\beta = 101.753(8)^\circ$, volume = $1628.5(14) \text{ \AA}^3$, are based upon the refinement of the XYZ-centroids of 7950 reflections above $20 \sigma(I)$ with $5.001^\circ < 2\theta < 55.31^\circ$. Data were corrected for absorption effects using the multi-scan method (SADABS). The ratio of minimum to maximum apparent transmission was 0.807.



The structure was solved and refined using the Bruker SHELXTL Software Package, using the space group $P 1 21/c 1$, with $Z = 4$ for the formula unit, $C_{18}H_{16}N_5O_2$. The final anisotropic full-matrix least-squares refinement on F^2 with 239 variables converged at $R1 = 7.36\%$, for the observed data and $wR2 = 21.33\%$ for all data. The goodness-of-fit was 1.106. The largest peak in the final difference electron density synthesis was $0.448 \text{ e}^-/\text{\AA}^3$ and the largest hole was $-0.485 \text{ e}^-/\text{\AA}^3$ with an RMS deviation of $0.089 \text{ e}^-/\text{\AA}^3$. On the basis of the final model, the calculated density was 1.364 g/cm^3 and $F(000)$, 700 e^- .

The crystal structure for **D30** has been deposited at the Cambridge Crystallographic Data Center and allocated the reference no. CCDC 909191.



4. ^1H NMR and ^{13}C NMR





A2





A3





C1





D1





D2



D3





D4





D5



S25





D6





D7





D8





D9





D10





D11





D12





D13





D14





D15





D16





D17





D18





D19





D20





D21





D22





D23





D24





D25





D26





D27



D28





D29





D30

S50





D31

S51





D32

S52





D33



S53





D34





D35





D36





D37



D38



D39



D40